All
What Breast Cancer Taught Me About Saying Yes to the Picture
After two bouts of breast cancer and a double mastectomy, I wish I had taken that photo at 34, just for me to remember the body I once had.
Daraxonrasib Gains FDA Status for Certain Metastatic Pancreatic Cancer
Daraxonrasib has received breakthrough therapy designation from the FDA for KRAS G12+, previously treated, metastatic pancreatic ductal adenocarcinoma.
Providing Advocacy and Support for Those With Pediatric Brain Cancer
Kasey Rangan discusses ways that families of patients with pediatric brain cancer can advocate for themselves, especially when it comes to mental health.
A New Digital Platform Aims to Expand Access to Early Oncology Trials
The START Hope Hub is a robust digital platform designed to break down barriers to early-phase clinical trial access for those with cancer.
FDA Approves Datroway for EGFR-Mutated Advanced Lung Cancer
Datroway received accelerated FDA approval for adults with EGFR+ advanced non-small cell lung cancer after EGFR-targeted and platinum chemotherapy.
Living My Best Life: A Family Beach Vacation After a Brain Tumor
After a brain tumor diagnosis and infection, I celebrate recovery with family at the beach, embracing life’s precious moments together.
Spotlighting Pancreatic Cancer Disparities in Black Communities
Tripp Razor highlights the disproportionately high pancreatic cancer risk among Black Americans and the systemic disparities they face in access to care.
Illuccix is FDA Approved to Guide Radioligand Use in Prostate Cancer
Illuccix is now FDA approved to help select patients with metastatic prostate cancer for radioligand therapy before chemotherapy.
What Should Patients with Multiple Myeloma Know After ASCO 2025?
Dr. Joshua Sabari and Dr. Nausheen Ahmed sat down to discuss topline takeaways in the realm of hematologic malignancies following the 2025 ASCO Meeting.
Improving Distant Control in Lung Cancer With JNJ-1900 and Keytruda
Combining JNJ-1900 with Keytruda may improve distant control of lung cancer, explained by Dr. Jared Weiss.
Experts Impart Notable Information and Updates for Those With Blood Cancers
The 2025 ASCO Annual Meeting brought many different updates to light in the realm of hematological malignancies, including multiple myeloma and lymphoma.
Breaking Down Clinical Trial Participation in Kidney Cancer: Is it Right for You?
Dr. Michael Serzan emphasizes the importance of clinical trial participation for patients with kidney cancer.
What Patients With Polycythemia Vera Should Know After ASCO 2025
Patients with blood cancers like polycythemia vera, a kind of myeloproliferative neoplasm, may benefit in learning more about recent data from ASCO 2025.
Radiation and Resilience: Laughing Through the Hardest Days
It’s a bad day when a doctor says you have cancer. It’s a worse day when he says it’s stage prostate cancer with a metastatic lesion.
Clinical Trial Corner: New Treatments in Leukemia, Lymphoma and Brain Cancers
Trials enrolling patients with relapsed leukemia, lymphoma and brain cancers, respectively, report early data showing safety/activity with novel therapies.
The Path Forward: Thriving in Cancer Survivorship
Surviving cancer wasn’t the end of my story; it was the start of redefining life, finding purpose and offering hope to those walking behind me.
Advancements Reshape Treatment for Non-Small Cell Lung Cancer
Dr. Prantesh Jain and Dr. Joshua Sabari delved into the numerous advances in NSCLC following 2025 ASCO, highlighting the REZILIENT-1 and NeoADAURA trials.
Personalized Therapy Helps Tailor Treatment for GIST
Dr. Breelyn Wilky explains that personalized treatments are helping improve outcomes for patients with gastrointestinal stromal tumors.
Can ctDNA Help Guide Surgical Decision Making in Breast Cancer
Dr. Rita Mukhtar and Dr. Joshua K. Sabari discuss the role of ctDNA to guide surgical decision-making after neoadjuvant chemo in breast cancer treatment.
Self-Advocacy Can Help Patients Navigate Cancer Treatment Challenges
Speaking up during cancer treatment helped one patient manage side effects, address insurance issues and stay productive throughout chemotherapy.
Experts Walk Through Recent Hematologic Malignancy Treatment Updates
Dr. Raajit K. Rampal and Dr. Joshua K. Sabari walk through updates for patients in the treatment of blood cancers, including polycythemia vera.
Breaking Down the Impact of SERENA-6 for Some With Breast Cancer
Dr. Joshua K. Sabari and Dr. Julia E. McGuinness discussed the SERENA-6 trial and its outcomes for patients with ESR1-mutated HR+/HER2— breast cancer.
Why I Don’t Call Myself a Survivor With Metastatic Breast Cancer
Living with metastatic breast cancer, I find it hard to relate to the term “survivor.”
Why is Clinical Trial Enrollment Important for Those With Kidney Cancer?
Dr. Michael Serzan explains the importance of clinical trial enrollment for patients with kidney cancer and highlighted findings from the STELLA-002 trial.
FDA Updates Talzenna-Xtandi Label for HRR-Mutated Metastatic Prostate Cancer
FDA approves updated labeling for Talzenna plus Xtandi in men with HRR gene-mutated metastatic prostate cancer, showing a 14-month survival benefit.
Exploring Palliative and Curative Radiation for Lung Cancer
Dr. Jared Weiss explained that radiation for lung cancer may ease symptoms or aim to cure, with newer targeted forms potentially boosting immune responses.
When a “Thinking of You” Card Isn’t the Right Support for a Patient
Those of us who’ve survived our cancer treatment journeys need to be role models to those who follow us.
FDA Approves Monjuvi With Revlimid and Rituxan for Follicular Lymphoma
The FDA approved Monjuvi with Revlimid and Rituxan for R/R follicular lymphoma after it showed significantly longer progression-free survival vs placebo.
Recent SCLC Data May Impact How Patients Are Treated Day-to-Day
Various trials within the small cell lung cancer space were brought to light following recent data, impacting how patients will be treated in the future.
I’m a Survivor: The Day I Finally Believed It
I finally felt like a survivor the day I heard my 18-month scans were clear, shifting from fear to faith and realizing I was not just surviving — I was thriving.
